SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 238 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $818,550 | -83.3% | 30,600 | -78.6% | 0.00% | -81.8% |
Q1 2024 | $4,887,963 | -25.6% | 143,300 | -36.9% | 0.01% | -26.7% |
Q4 2023 | $6,572,274 | +21.6% | 227,100 | +15.8% | 0.02% | +7.1% |
Q3 2023 | $5,406,477 | -35.6% | 196,100 | -29.8% | 0.01% | -33.3% |
Q2 2023 | $8,398,764 | -25.1% | 279,400 | -9.8% | 0.02% | -27.6% |
Q1 2023 | $11,220,431 | +45.6% | 309,700 | +43.4% | 0.03% | +31.8% |
Q4 2022 | $7,704,720 | +133.9% | 216,000 | +122.0% | 0.02% | +120.0% |
Q3 2022 | $3,294,000 | +695.7% | 97,300 | +580.4% | 0.01% | +900.0% |
Q2 2022 | $414,000 | -58.3% | 14,300 | -53.4% | 0.00% | -66.7% |
Q1 2022 | $992,000 | +52.6% | 30,700 | +37.7% | 0.00% | +50.0% |
Q4 2021 | $650,000 | +90.6% | 22,300 | +74.2% | 0.00% | +100.0% |
Q3 2021 | $341,000 | -87.2% | 12,800 | -85.3% | 0.00% | -85.7% |
Q2 2021 | $2,673,000 | -56.1% | 86,800 | -62.7% | 0.01% | -58.8% |
Q1 2021 | $6,095,000 | +69.2% | 232,800 | +62.6% | 0.02% | +70.0% |
Q4 2020 | $3,603,000 | -28.8% | 143,200 | -41.0% | 0.01% | -28.6% |
Q3 2020 | $5,058,000 | -48.8% | 242,700 | -41.7% | 0.01% | -51.7% |
Q2 2020 | $9,885,000 | +44.7% | 416,200 | +9.6% | 0.03% | +11.5% |
Q1 2020 | $6,833,000 | +122.3% | 379,800 | +193.1% | 0.03% | +271.4% |
Q4 2019 | $3,074,000 | -13.9% | 129,600 | -0.2% | 0.01% | -22.2% |
Q3 2019 | $3,570,000 | -67.2% | 129,900 | -60.5% | 0.01% | -66.7% |
Q2 2019 | $10,893,000 | +33.9% | 329,200 | +41.8% | 0.03% | +28.6% |
Q1 2019 | $8,136,000 | +1072.3% | 232,200 | +1901.7% | 0.02% | +950.0% |
Q2 2018 | $694,000 | +116.2% | 11,600 | +65.7% | 0.00% | +100.0% |
Q1 2018 | $321,000 | -59.5% | 7,000 | -62.0% | 0.00% | -66.7% |
Q2 2017 | $793,000 | +39.1% | 18,400 | +1.1% | 0.00% | +50.0% |
Q1 2017 | $570,000 | +26.1% | 18,200 | +1.7% | 0.00% | 0.0% |
Q4 2016 | $452,000 | +12.7% | 17,900 | +10.5% | 0.00% | 0.0% |
Q3 2016 | $401,000 | -9.3% | 16,200 | -55.7% | 0.00% | -33.3% |
Q1 2015 | $442,000 | – | 36,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |